Summary: Fatigue is not listed as a common side effect of Rybelsus in UK prescribing information, though some patients report tiredness which may relate to diabetes itself, dietary changes, gastrointestinal effects, or metabolic adjustment
Although insomnia is not listed as a primary or frequent side effect in clinical trials, a few mechanisms may explain sleep disturbances: Gastrointestinal Discomfort Nausea, bloating, or acid reflux common side effects of semaglutide may interfere with sleep, especially if the medication is taken late in the day
Food preferences often shift during this window
Providers who genuinely connect with their patients can better empower them to take an active role in their care and incorporate healthy lifestyle changes
Rybelsus Rybelsus made history in 2019 as the first oral GLP-1 receptor agonist to receive FDA approval